SugarGPT: Envisioning the Future of Glycoinformatics
The body’s autoimmune response has been leveraged by cancer researchers to propel immunotherapy tools into clinical use. Although the main focus has been on the ability of T-cells to fight cancer cells, the involvement of tumor-infiltrating B-cells is also becoming evident. Tumor-infiltrating B lymphocytes (TIL-Bs) are produced in much higher amounts in various cancers than in healthy tissues, which highlights their positive prognostic value (1). However, their exact role in cancer remains controversial, with the demonstration of both positive and negative impacts.